ArticleNPJ precision oncology2024

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.

Antonio Lahera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.